ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "informatics"

  • Abstract Number: 0391 • ACR Convergence 2024

    Using Machine Learning to Predict Inactive Disease in Juvenile Idiopathic Arthritis

    Mei-Sing Ong1, Marc Natter2, Laura Schanberg3 and Yukiko Kimura4, and CARRA Registry Investigators, 1Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, 2Boston Children's Hospital, Boston, MA, 3Duke University Medical Center, DURHAM, NC, 4Hackensack Meridian School of Medicine, New York, NY

    Background/Purpose: Optimizing treatment of JIA continues to be a challenge. Biologic DMARD (bDMARD) therapies have significantly improved outcomes but is costly, may be more difficult…
  • Abstract Number: 2621 • ACR Convergence 2024

    Trends in Disease Activity in Rheumatoid Arthritis over 2009-2023 Utilizing DAS28-CRP Inferred from Electronic Health Records

    David Cheng1, Vidul Panickan2, Andrew Cagan3, Gregory McDermott4, Mary Jeffway3, Ying Qi5, Feng Liu3, Michael Weinblatt6, Nancy Shadick5, Tianxi Cai7 and Katherine Liao3, 1Massachusetts General Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women’s Hospital, Brookline, MA, 5Brigham and Women’s Hospital, Boston, MA, 6Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 7Harvard T.H. Chan School of Public Health, Boston, MA

    Background/Purpose: Systematic measurement and documentation of disease activity in RA patients is key for monitoring quality of care and is an important outcome and predictor…
  • Abstract Number: 0456 • ACR Convergence 2024

    Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis

    Jeffrey Curtis1, Yujie Su2, Cassie Clinton3, David Curtis4, Laura Stradford5, Patrick Zueger6, William Benjamin Nowell7, Pankaj Patel8, Esteban Rivera9, Kelly Gavigan4, Shilpa Venkatachalam10 and Fenglong Xie3, 1FASTER Medicine, Hoover, AL, 2Illumination Health, Hoover, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Global Healthy Living Foundation, Upper Nyack, NY, 5Global Healthy Living Foundation, Nyack, NY, 6AbbVie Inc, North Chicago, IL, 7Regeneron, New York, NY, 8AbbVie Inc., North Chicago, IL, 9Global Healthy Living Foundation, Long Island City, NY, 10Global Healthy Living Foundation, New York, NY

    Background/Purpose: Digital health technology to collect electronic patient reported outcomes (ePRO) and biosensor data are increasingly used to generate real-world data in pharmacoepidemiology. However, the…
  • Abstract Number: 2692 • ACR Convergence 2024

    Transcriptomic Profiling of Kidney Biopsies Implicates Th17 and IL-17 in ANCA-Associated Vasculitis

    Ivana Stojkic1, Arnon Arazi2, Huijuan Song3, Pearlly Yan4, Estela Puchulu-Campanella3, Hubao Wang3, Lynn Fussner3, Brad Rovin3, Samir Parikh5, Stacy Ardoin6, Daniel Koboldt7, James Fitch7 and Salem Almaani8, 1Nationwide, Columbus, OH, 2Feinstein Institutes for Medical Research, Melrose, MA, 3The Ohio State University, Columbus, OH, 4The Ohio State University, Columbus, 5Ohio State University, Columbus, OH, 6Nationwide Children's Hospital, Columbus, OH, 7Steve and Cindy Rasmussen Institute for Genomic Medicine, Columbus, OH, 8The Ohio State University Medical Center, Columbus, OH

    Background/Purpose: ANCA-associated vasculitis (AAV) is a severe autoimmune disease targeting small vessels, with significant kidney involvement. Despite current therapies, up to 28% of patients progress…
  • Abstract Number: 0608 • ACR Convergence 2024

    Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort

    Andrew Concoff1, Touba Warsi2, Sepehr Taghavi2, Sudha Kumar2, Abigail Patalinghug2, Christine Schleif2, Brittany Partain3, Joseph Ahearn4, Chau-Ching Liu5, Nicole Wilson5, Susan Manzi5 and Tyler O'Malley6, 1Exagen, Inc., Los Angeles, CA, 2Exagen, Carlsbad, CA, 3Exagen, Boston, MA, 4Allegheny Health Network, Wexford, PA, 5Allegheny Health Network, Pittsburgh, PA, 6Exagen, Vista, CA

    Background/Purpose: Cell bound complement activation products (CB-CAPs) including erythrocyte-bound C4d (EC4d) and B-lymphocyte C4d (BC4d) demonstrate increased diagnostic accuracy compared to conventional SLE markers (anti-dsDNA,…
  • Abstract Number: 0709 • ACR Convergence 2024

    Linear Combination of Principal Components Achieves Top Performance in Identifying Rheumatologist-Diagnosed Systemic Sclerosis from Electronic Health Records

    Yiming Luo, Gongbo Zhang, Chunhua Weng and Elana Bernstein, Columbia University Irving Medical Center, New York, NY

    Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune rheumatic disease. International Classification of Diseases (ICD) code counts (for example, using ≥ 2 ICD-10 codes…
  • Abstract Number: 0728 • ACR Convergence 2024

    Glomerular Proteomic Signature in ANCA-associated Glomerulonephritis

    Ivana Stojkic1, Arnon Arazi2, Huijuan Song3, Pearlly Yan4, Estela Puchulu-Campanella4, Hubao Wang3, Lynn Fussner3, Brad Rovin3, Samir Parikh5 and Salem Almaani6, 1Nationwide, Columbus, OH, 2Feinstein Institutes for Medical Research, Melrose, MA, 3The Ohio State University, Columbus, OH, 4The Ohio State University, Columbus, 5Ohio State University, Columbus, OH, 6The Ohio State University Medical Center, Columbus, OH

    Background/Purpose: Crescentic glomerulonephritis (AAGN) is a common manifestation of ANCA-associated vasculitis (AAV) but does not occur in all patients. It is unclear whether the immune…
  • Abstract Number: 1598 • ACR Convergence 2023

    Single-cell Spatial Proteomics Identifies Intraglomerular Myeloid Cells in Membranous Lupus Nephritis

    Chen-Yu Lee1, Caleb Marlin2, Xiaoping Yang1, Tayte Stephens2, Alessandra Ida Celia3, Jeff Hodgin4, Peter Izmirly5, H Michael Belmont6, Jill Buyon7, Chaim Putterman8, Judith James2, the Accelerating Medicines Partnership in RA/SLE9, Michelle Petri10, Joel Guthridge2, Avi Rosenberg11 and Andrea Fava1, 1Johns Hopkins University, Baltimore, MD, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3John Hopkins University of Medicine, Rome, Italy, 4University of Michigan, Ann Arbor, MI, 5New York University School of Medicine, New York, NY, 6NYU School of Medicine, New York, NY, 7NYU Grossman School of Medicine, New York, NY, 8Albert Einstein College of Medicine, Bronx, NY, 9Multiple, Multiple, 10Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 11Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Lupus nephritis (LN) leads to end-stage kidney disease (ESKD) in more than 20% of patients despite optimal treatment. Up to 30% of LN patients…
  • Abstract Number: 1696 • ACR Convergence 2023

    Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis

    Michael A. Smith1, Dominic Sinibaldi2, Saifur Rahman1, Chia-Chien Chiang2, Anna M. Hansen1, Jill Henault1, Carlos P. Roca3, Shu Wang1, Kamelia Zerrouki1, Rebecca Filippi1, Christopher Groves1, Zerai Manna4, Jun Chu4, Michael Davis4, sarthak gupta4, Christopher Morehouse1, Melissa De los Reyes1, Rachel Ettinger1, Roland Kolbeck1, Mariana Kaplan5, Miguel A. Sanjuan1, Richard M. Siegel6, sarfaraz Hasni4 and Kerry A. Casey1, 1BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Data Science and AI, AstraZeneca, Gaithersburg, MD, 3Data Science and AI, AstraZeneca, Cambridge, United Kingdom, 4Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 5Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 6Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
  • Abstract Number: 1903 • ACR Convergence 2023

    Assessing Disparities Through Missing Race and Ethnicity Data: Results from a Juvenile Arthritis Registry

    Katelyn Banschbach1, Jade Singleton2, Esi Morgan2 and Xing Wang3, 1University of Washington, Seattle, WA, 2Seattle Children's Hospital, Seattle, WA, 3Biostatistics Epidemiology and Analytics in Research (BEAR), Seattle Children’s Research Institute, Seattle, WA

    Background/Purpose: Research databases are missing 25-50% of race and ethnicity, typically related to Black and Hispanic data.1,2The absence of this data can lead to inaccurate…
  • Abstract Number: 1911 • ACR Convergence 2023

    Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study

    Catherine Nasrallah1, Cherish Wilson2, Alicia Hamblin1, Lindsay Jacobsohn1, Cammie Young3, Cammie Young3, Mary Nakamura4, Andrew Gross1, Judith Ashouri1, Mehrdad Matloubian1, Jinoos Yazdany1 and Gabriela Schmajuk2, 1University of California San Francisco, San Francisco, CA, 2UCSF / SFVA, San Francisco, CA, 3University of California San Francisco, Oakland, CA, 4UCSF/SFVAHCS, San Francisco, CA

    Background/Purpose: Improving shared decision-making using a treat-to-target approach, including the use of patient reported outcomes (PROs), is important to providing high quality care for rheumatoid…
  • Abstract Number: 2070 • ACR Convergence 2023

    Augmenting Medical Education: An Evaluation of GPT-4 and ChatGPT in Answering Rheumatology Questions from the Spanish Medical Licensing Examination

    Alfredo Madrid García1, zulema Rosales2, Dalifer Freites2, Inés Pérez Sancristóbal3, Benjamin Fernandez3 and Luis Rodríguez Rodríguez3, 1Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, 2Hospital Clínico San Carlos, Madrid, Spain, 3Hospital Clinico San Carlos, Madrid, Spain

    Background/Purpose: The emergence of Large Language Models (LLM) with remarkable performance such as GPT-4 and ChatGPT, has led to an unprecedented uptake in the population.…
  • Abstract Number: 2323 • ACR Convergence 2023

    An Electronic Health Record-Based Algorithm for Predicting Systemic Lupus Erythematosus Flares: Integrating Clinical Factors and Social Determinants of Health

    Yu Huang1, Lixia Yao2, zhengkang Fan3, Jingchuan Guo1 and Jiang Bian1, 1University of Florida, Gainesville, FL, 2Polygon Health Analytics LLC, Chalfont, PA, 3University of Florida, Gainsville, FL

    Background/Purpose: Systemic lupus erythematosus (SLE) has a relapsing-remitting course, with patients experiencing disease activity flares over time. Flares and prolonged disease activity are associated with…
  • Abstract Number: 2586 • ACR Convergence 2023

    A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis

    Peter C. Taylor1, Jenya Antonova2, Jennifer Geis3, Katharine Dilger3, David Chernoff4, Diana Abdueva3, Nancy Shadick5 and Michael Weinblatt6, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Compass Strategy and Research, Inc., San Francisco, CA, 3Aqtual Inc., Hayward, CA, 4Chernoff Consulting, Sausalito, CA, 5Brigham and Women's Hospital, Boston, MA, 6Harvard Medical School, Waban, MA

    Background/Purpose: Non-invasive differentiation of seropositive and seronegative rheumatoid arthritis (RA) from other conditions has been limited in the current practice. We aimed to evaluate the…
  • Abstract Number: 0163 • ACR Convergence 2023

    Uncovering Discrepancies: Analysis of Glucocorticoid Exposure Among Patients with Rheumatoid Arthritis in Electronic Health Record Data versus Medicare Claims

    Jing Li1, Julia Kay1, Sharon Abada1, Andriko Palmowski2, Rachael Stovall1, Jinoos Yazdany3 and Gabriela Schmajuk4, 1University of California San Francisco, San Francisco, CA, 2Charité - Universitätsmedizin Berlin, Berlin, Germany, 3University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, 4UCSF / SFVA, San Francisco, CA

    Background/Purpose: Understanding glucocorticoid (GC) exposure is critical for observational analyses in rheumatology. However, obtaining an accurate measure of GC exposure, including dosage and duration, has…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology